Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BBNX
SELLBeta Bionics, Inc. · Healthcare · United States · $706M · Avg Vol: $17M/d
COMPANY DESCRIPTION
Beta Bionics, Inc. is a medical technology company focused on transforming diabetes management through its innovative iLet Bionic Pancreas system, an FDA-approved autonomous insulin delivery device. This system aims to simplify glucose control for users by independently adjusting insulin dosages. Its unique algorithm and potential for dual-hormone delivery position it as a significant player in the rapidly advancing automated insulin delivery market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.2M | 12.0M | 65.1M | 100.3M | 724.3% | 110.2M | 133.3M | 179.6M | 33.8% |
| EPS | -2.12 | -1.45 | -1.28 | -1.81 | — | -1.41 | -2.11 | -2.39 | — |
| Shares | 42.9M | 42.9M | 42.9M | 44.4M | +3.5% | 44.6M | — | — | — |
| Debt | 4.1M | 4.2M | 7.3M | 7.3M | 20.9% | 6.9M | — | — | — |
| Equity | -170.0M | -203.1M | -245.4M | 287.6M | — | — | — | — | — |
| Op CF | -60.2M | -32.4M | -48.3M | -50.9M | — | -54.8M | — | — | — |
| Inv CF | -0.8M | -69.7M | -3.5M | -162.8M | — | — | — | — | — |
| Fin CF | 56.8M | 101.0M | 55.6M | 214.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BBNX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BBNX | Beta Bionics, Inc.(you) | $706M | 22 | SELL |
| CBLL | CeriBell, Inc. | $642M | 24 | SELL |
| AORT | Artivion, Inc. | $1.2B | 22 | SELL |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 26 | SELL |
| TNDM | Tandem Diabetes Care, Inc. | $1.2B | 25 | SELL |
| PRCT | PROCEPT BioRobotics Corporation | $950M | 14 | STRONG SELL |
| IMR.AX | Imricor Medical Systems, Inc. | $455M | 15 | STRONG SELL |
| LAB | Standard BioTools Inc. | $326M | 22 | SELL |
| ATEC | Alphatec Holdings, Inc. | $1.3B | 27 | SELL |
| CLPT | ClearPoint Neuro, Inc. | $423M | 13 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%